Cleveland, MS3 Active Studies

Benign Prostatic Hyperplasia Clinical Trials in Cleveland, MS

Find 3 actively recruiting benign prostatic hyperplasia clinical trials in Cleveland, MS. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
106
Enrolling

Recruiting Benign Prostatic Hyperplasia Studies in Cleveland

About Benign Prostatic Hyperplasia Clinical Trials in Cleveland

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can cause urinary symptoms in men. It becomes increasingly common with age, affecting most men over 50. Treatment includes alpha-blockers, 5-alpha reductase inhibitors, and minimally invasive procedures.

There are currently 3 benign prostatic hyperplasia clinical trials recruiting participants in Cleveland, MS. These studies are seeking a combined 106 participants. Research is being sponsored by Smita De, The Cleveland Clinic. Clinical trial participation is free and participants receive study-related medical care at no cost.

Benign Prostatic Hyperplasia Clinical Trials in Cleveland — FAQ

Are there benign prostatic hyperplasia clinical trials in Cleveland?

Yes, there are 3 benign prostatic hyperplasia clinical trials currently recruiting in Cleveland, MS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cleveland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you about next steps.

Are clinical trials in Cleveland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cleveland studies also compensate for your time and travel.

What benign prostatic hyperplasia treatments are being tested?

The 3 active trials in Cleveland are testing new therapies including novel drugs, biologics, and treatment approaches for benign prostatic hyperplasia.

Data updated July 13, 2026 from ClinicalTrials.gov